Structure Therapeutics
Specializes in the discovery and development of drugs against a type of targets called GPCR.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 -9.5x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $476m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (605 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (401 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Structure Therapeutics is a clinical-stage biopharmaceutical company that specializes in the discovery and development of oral small molecule therapeutics for the treatment of chronic metabolic diseases. The company leverages its expertise in structure-based drug design to create more accessible and effective treatments.
Operating in the biopharmaceutical market, Structure Therapeutics focuses on developing innovative drugs for a range of metabolic disorders. Its business model is centered on a science-driven approach to drug discovery, advancing promising candidates through clinical trials. The company generates revenue through the development and commercialization of its proprietary drug candidates.
Keywords: biopharmaceutical, clinical-stage, drug design, metabolic diseases, oral therapeutics, small molecules, structure-based, GLP-1, GPCR, chronic illness